In addition, according to the European Neuroendocrine Tumor Society (ENETS) Guidelines, a systemic cytotoxic treatment is recommended in progressive or bulky advanced NETs localized in the pancreas or in other sites when there is a high Ki-67, rapidly progressive disease, and after the failure of other therapies if SSTR-imaging is negative [96]. This evidence concerns the gene MKI67 and neoplasm.